Home / Leaderboard / Fairmount Funds Management LLC
Fairmount Funds Management LLC
Peter Harwin · Hedge Fund · Long/Short Equity
Fairmount Funds Management LLC is a Philadelphia-based investment firm founded in 2019 that specializes in the life sciences and healthcare sectors. The firm focuses on identifying and investing in biotechnology companies with the potential to develop transformative therapies. Managing over $3 billion in assets, Fairmount employs a fundamental, research-driven approach to build a concentrated portfolio of both public and private equities. The team leverages deep scientific and clinical expertise to uncover value in clinical-stage companies and often participates in significant financing rounds to support long-term growth and innovation in the therapeutic space.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +198.4% |
| YTD return | +72.1% |
| Sharpe ratio | 2.92 |
| Win rate | 94% |
| AUM | $2.3B |
| Inception | Oct 1, 2025 |
| Updated | Aug 20, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $2.3B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.fairmountfunds.com/ |
Current Holdings
Updated on Aug 20, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. Common Stock | 38.1% | +144.3% |
| ORKA | Oruka Therapeutics, Inc. | 13.5% | +155.4% |
| DMRA | Damora Therapeutics, Inc. | 11.2% | +12.9% |
| DNTH | Dianthus Therapeutics Inc. | 10.2% | +78.5% |
| COGT | Cogent Biosciences Inc | 9.2% | +72.1% |
| VRDN | Viridian Therapeutics Inc | 4.2% | +16.4% |
| JBIO | Jade Biosciences, Inc. | 4.2% | +67.9% |
| ELVN | Enliven Therapeutics Inc. | 4.0% | +107.7% |
| ZBIO | Zenas BioPharma, Inc. Common Stock | 2.7% | +40.6% |
| CBIO | Crescent Biopharma, Inc. | 2.0% | +34.6% |
| IKT | Inhibikase Therapeutics Inc | 0.7% | +36.7% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Jul 6, 2026 | BUY | ZBIO | 2.0% → 2.7% |
| Jul 6, 2026 | BUY | COGT | 8.2% → 9.2% |
| Jul 6, 2026 | SELL | SYRE | 13.2% → 0.0% |
| Jul 6, 2026 | BUY | CBIO | 1.8% → 2.0% |
| Jul 6, 2026 | BUY | IKT | 0.6% → 0.7% |
Investment Style Analysis
Fairmount Funds Management LLC is widely recognized for employing a Long/Short Equity strategy. As of Aug 20, 2026, the firm oversees approximately $2.3B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Jul 6, Fairmount Funds Management LLC made a significant move by increasing exposure to ZBIO. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Fairmount Funds Management follows a fundamental, research-driven investment philosophy focused on the life sciences and healthcare industries. The firm targets high-conviction opportunities in biotechnology, where scientific innovation and clinical data create significant value-creation potential. By maintaining a concentrated investment strategy and engaging deeply with management teams, Fairmount seeks to identify and capitalize on mispriced assets. Their strategy encompasses both public equities and private investments, often participating in financing rounds to help bring novel therapeutic solutions to market and capitalize on event-driven catalysts.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Fairmount Funds Management LLC.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M +24.1%
- Glenview Capital Management, LLC — Larry Robbins · 3M +14.0%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +3.7%
- Redmile Group, LLC — Jeremy Green · 3M +19.6%
Frequently asked questions
How is the simulated portfolio for Fairmount Funds Management LLC constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Fairmount Funds Management LLC's largest holding?
As of the latest filing, Fairmount Funds Management LLC's top position is Apogee Therapeutics, Inc. Common Stock (APGE), representing 38.1% of the portfolio. This reflects a high-conviction bet by the institution.
What is Fairmount Funds Management LLC's historical performance and risk profile?
Our simulation indicates a total return of +198.4% with a win rate of 94%. Notably, the portfolio maintains a Sharpe Ratio of 2.92, suggesting an excellent level of risk-adjusted returns compared to the broader market.
What sectors does Fairmount Funds Management LLC primarily invest in?
Fairmount Funds Management LLC has a strong preference for the Biotechnology sector, which makes up 100.0% of their disclosed assets. The portfolio also has exposure to other industries, indicating a specific thematic focus.
Is Fairmount Funds Management LLC's portfolio concentrated or diversified?
Fairmount Funds Management LLC runs a highly concentrated portfolio with 11 disclosed positions. The top 3 holdings alone account for 62.8% of the total portfolio weight, suggesting a strategy that favors deep research into a few key names.
How has Fairmount Funds Management LLC performed in 2026?
Our AI-simulated model portfolio for Fairmount Funds Management LLC tracks a Year-to-Date (YTD) return of +72.1%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Peter Harwin manage Fairmount Funds Management LLC directly?
Yes, Peter Harwin serves as the key portfolio manager for Fairmount Funds Management LLC, overseeing the investment strategy and final capital allocation decisions.